Liposomal Borrelidin for Treatment of Metastatic Breast Cancer

Integration Core

Authors Moonkyoung Jeong, Heegon Kim, Sunghoon Kim, Ji-Ho Park
Journal Drug Delivery and Translational Research
Vol.(no.) 8(5)
Pages 1380-1388
Year 20180710
Attach Jeong2018_Article_LiposomalBorrelidinForTreatmenapplication/pdf


Borrelidin is an inhibitor of threonyl-tRNA synthetase with both anticancer and antiangiogenic activities. Although borrelidin could be a potent drug that can treat metastatic cancer through synergistic therapeutic effects, its severe liver toxicity has limited the use for cancer therapeutics. In this study, we developed a liposomal formulation of borrelidin to treat metastatic breast cancer effectively through its combined anticancer and antiangiogenic effects while reducing the potential liver toxicity. The liposomal formulation was optimized to maximize loading stability and efficiency of lipophilic borrelidin in the liposomal membrane and its delivery efficiency to primary tumor in a mouse model of metastatic breast cancer. Liposomal borrelidin showed significant in vitro therapeutic effects on proliferation and migration of tumor cells and angiogenesis of endothelial cells. Furthermore, liposomal borrelidin exhibited superior inhibitory effects on primary tumor growth and lung metastasis in vivo compared to free borrelidin. More importantly, liposomal borrelidin did not induce any significant systemic toxicity in the mouse model after multiple injections.


We're not around right now. But you can send us an email and we'll get back to you, asap.


©2010-2024 Medicinal Bioconvergence Research Center. All rights reserved.

Log in with your credentials

Forgot your details?